Business Description
ADMA Biologics Inc
NAICS : 325412
SIC : 2834
ISIN : US0008991046
Share Class Description:
ADMA: Ordinary SharesTotal Employee Number:
647Description
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing, which generates maximum revenue, Plasma Collection Centres, and the corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling & packing services. The company derives maximum revenue from the United States.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.67 | |||||
Equity-to-Asset | 0.6 | |||||
Debt-to-Equity | 0.5 | |||||
Debt-to-EBITDA | 0.88 | |||||
Interest Coverage | 24.53 | |||||
Piotroski F-Score | 5/9 | |||||
Altman Z-Score | 7.21 | |||||
Beneish M-Score | -2.41 | |||||
WACC vs ROIC | ||||||
Growth Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 38.8 | |||||
3-Year Book Growth Rate | 43.1 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 22.82 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 13.13 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 48.5 | |||||
9-Day RSI | 52.97 | |||||
14-Day RSI | 54.71 | |||||
3-1 Month Momentum % | 1.47 | |||||
6-1 Month Momentum % | -45.52 | |||||
12-1 Month Momentum % | -51.64 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 6.97 | |||||
Quick Ratio | 3.81 | |||||
Cash Ratio | 1.8 | |||||
Days Inventory | 426.36 | |||||
Days Sales Outstanding | 96.89 | |||||
Days Payable | 51.9 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -2.4 | |||||
Shareholder Yield % | 4.69 |
Profitability Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 64.71 | |||||
Operating Margin % | 42.26 | |||||
Net Margin % | 32.98 | |||||
EBITDA Margin % | 45.48 | |||||
FCF Margin % | 22.69 | |||||
OCF Margin % | 26.69 | |||||
ROE % | 40.13 | |||||
ROA % | 27.24 | |||||
ROIC % | 36.89 | |||||
3-Year ROIIC % | 76.65 | |||||
ROC (Joel Greenblatt) % | 61.77 | |||||
ROCE % | 40.96 | |||||
Years of Profitability over Past 10-Year | 2 | |||||
Moat Score | 5 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 13.76 | |||||
Forward PE Ratio | 12.35 | |||||
PE Ratio without NRI | 14.14 | |||||
Price-to-Owner-Earnings | 20.29 | |||||
PS Ratio | 4.5 | |||||
PB Ratio | 5.32 | |||||
Price-to-Tangible-Book | 5.38 | |||||
Price-to-Free-Cash-Flow | 19.79 | |||||
Price-to-Operating-Cash-Flow | 16.88 | |||||
EV-to-EBIT | 9.87 | |||||
EV-to-EBITDA | 9.55 | |||||
EV-to-Revenue | 4.34 | |||||
EV-to-Forward-Revenue | 4.22 | |||||
EV-to-FCF | 19.14 | |||||
Price-to-GF-Value | 0.53 | |||||
Price-to-Projected-FCF | 12.51 | |||||
Price-to-Median-PS-Value | 0.86 | |||||
Price-to-Graham-Number | 1.84 | |||||
| Price-to-Net-Current-Asset-Value | 8.6 | |||||
Earnings Yield (Greenblatt) % | 10.13 | |||||
FCF Yield % | 5.39 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:ADMA
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
ADMA Biologics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 512.275 | ||
| EPS (TTM) ($) | 0.7 | ||
| Beta | 1.3438 | ||
| 3-Year Sharpe Ratio | 0.62 | ||
| 3-Year Sortino Ratio | 1.07 | ||
| Volatility % | 59.48 | ||
| 14-Day RSI | 54.71 | ||
| 14-Day ATR ($) | 0.341215 | ||
| 20-Day SMA ($) | 9.48775 | ||
| 12-1 Month Momentum % | -51.64 | ||
| 52-Week Range ($) | 7.2101 - 20.458 | ||
| Shares Outstanding (Mil) | 223.98 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
ADMA Biologics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
ADMA Biologics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Fourth quarter earnings conference call for 2026 | 2027-02-25 16:30 | In 183 days | ||
| Annual report for 2026 | 2027-02-25 | In 182 days | ||
| Fourth quarter earnings results for 2026 | 2027-02-25 | In 182 days | ||
| Third quarter earnings conference call for 2026 | 2026-11-05 16:30 | In 71 days | ||
| Third quarter earnings results for 2026 | 2026-11-05 | In 70 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-05 16:30 | 8.91 (+2.53%) | ||
| Second quarter earnings results for 2026 | 2026-08-05 | 8.91 (+2.53%) | ||
| General meeting for 2026 | 2026-06-02 10:00 | 7.90 (-1.00%) | ||
| First quarter earnings conference call for 2026 | 2026-05-06 16:30 | 10.25 (-1.73%) | ||
| First quarter earnings results for 2026 | 2026-05-06 | 10.25 (-1.73%) |
Show
Entries
ADMA Biologics Inc Frequently Asked Questions
What is ADMA Biologics Inc(ADMA)'s stock price today?
The current price of ADMA is $9.63. The 52 week high of ADMA is $20.46 and 52 week low is $7.21.
When is next earnings date of ADMA Biologics Inc(ADMA)?
The next earnings date of ADMA Biologics Inc(ADMA) is 2026-11-05 Est..
Does ADMA Biologics Inc(ADMA) pay dividends? If so, how much?
ADMA Biologics Inc(ADMA) does not pay dividend.
Guru Commentaries on NAS:ADMA
Aug 5, 2025
Bullish
2025 Q2
What the manager wrote
During the quarter we added several new ideas, including Insmed, ADMA Biologics, HealthEquity, Waystar, and Alignment Healthcare. Biotech continues to be a significant weight in the R2500G, and we continue to believe commercial stage companies with marketed products have strong growth prospects. ADMA has unique manufacturing capabilities for plasma-derived therapeutics and should continue to gain market share and drive profitable growth for the next several years.
2025 Q1
small cap quality growth q1 commentary
What the manager wrote
ADMA Biologics (ADMA) had another outstanding quarter and guided metrics higher. This performance is indicative of the company's strong position within the health care sector, particularly in biotechnology. The positive guidance suggests that ADMA is well-positioned for future growth, aligning with our strategy of investing in high-quality growth companies. The overall performance of our portfolio, which includes ADMA, reflects our focus on companies that exhibit stable, consistent growth and attractive valuations.
Press Release
Articles on ADMA Biologics Inc
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers